Safety data on in situ gelling bimatoprost loaded nanovesicular formulations.

Monika Yadav, Ana Guzman-Aranguez, Maria J Perez de Lara, Mandeep Singh, Joga Singh, Indu Pal Kaur

Open access · goldAbstract read

In one paragraph

Article in Data in brief, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 37% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

From Eye Care to Hair Growth: Bimatoprost.Pharmaceuticals (Basel, Switzerland) · 2024
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Monika YadavUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.

Ana Guzman-AranguezFaculty of Optics and Optometry, Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain.

Maria J Perez de LaraFaculty of Optics and Optometry, Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain.

Mandeep SinghUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.

Joga SinghUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.

Indu Pal KaurUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.

Panjab University · INUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vitro cytotoxicity and in vivo acute and 7 days repeat-dose ocular toxicity studies, were conducted in rabbits, in accordance with the Organisation for Economic Co-operation and Development (OECD) guidelines, for bimatoprost loaded nanovesicular aqueous dispersion (BMT-NV) and its in-situ gelling sub-conjunctival implant (BMT-NV-IM). For details on the preparation and evaluation of BMT-NV and its BMT-NV-IM for the control of glaucoma, please refer to 'Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation' (Yadav et al., 2019). The in vivo ocular toxicity was performed only after confirming dermal safety, as required by OECD. Histological evaluation of various ocular tissues, following sub-conjunctival implantation with BMT-NV-IM, was done for ocular tolerance studies.

Indexed as

Acute and repeat dose toxicityCell linesCytotoxicityIn situ gellingOcular toxicitySub-conjunctival implants

Identifiers

PMID31485469

DOI10.1016/j.dib.2019.104361

PMCPMC6715818

OpenAlexW2966368605

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.